Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Washington University School of Medicine
Orca Biosystems, Inc.
Taiho Oncology, Inc.
Center for International Blood and Marrow Transplant Research
Takeda
Thomas Jefferson University
Cogent Biosciences, Inc.
Ossium Health, Inc.
Memorial Sloan Kettering Cancer Center
Center for International Blood and Marrow Transplant Research
University of Michigan Rogel Cancer Center
Constellation Pharmaceuticals
Dana-Farber Cancer Institute
Fred Hutchinson Cancer Center
Cogent Biosciences, Inc.
Novartis
Cellenkos, Inc.
Masonic Cancer Center, University of Minnesota
Sierra Oncology LLC - a GSK company
Baptist Health South Florida
Takeda
Baylor College of Medicine
NS Pharma, Inc.
Hoffmann-La Roche
Takeda
CTI BioPharma
University of Rochester
Novartis
University of Illinois at Chicago
AOP Orphan Pharmaceuticals AG
Pfizer
Novartis
Phoenix Children's Hospital
Bellicum Pharmaceuticals
CTI BioPharma
Gilead Sciences
Sierra Oncology LLC - a GSK company
Novartis
M.D. Anderson Cancer Center
Celgene
Fred Hutchinson Cancer Center
Novartis
Celgene
Il-Yang Pharm. Co., Ltd.
Sunesis Pharmaceuticals
M.D. Anderson Cancer Center
Beth Israel Deaconess Medical Center
Baylor College of Medicine
National Heart, Lung, and Blood Institute (NHLBI)